Pharma BD Deal Intelligence

Alkermes plc / Rodin Therapeutics, Inc.

2019 · Acquisition/Merger · $950M · Complete

Alkermes paid $100M upfront for Rodin Therapeutics' preclinical HDAC-CoREST inhibitors worth up to $950M, but lead candidate ALKS 1140 was terminated in Phase 1 by 'Sponsor Decision' after just 20 patients, leaving the $850M milestone tail unrealized.

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Nov 18, 2019 BioPharma Dive Neutral

Alkermes' Rodin acquisition came on the heels of cost-cutting and was framed as a strategic pivot toward CNS depth; analysts noted Rodin's preclinical stage…

Nov 18, 2019 LifeSciVC Bullish

LifeSciVC framed the deal as a vindication of Atlas Venture's bold thesis that selective HDAC-CoREST inhibition could safely modulate epigenetic synaptogenesis…

Nov 19, 2019 Pharmaphorum Neutral

Alkermes' bolt-on of Rodin was characterized as a pipeline-thickening move with milestone-heavy economics, though commentators questioned whether preclinical…

Source summaries from our enrichment pipeline; follow links for originals.

All 7 sources with sentiment breakdown →

Alkermes acquired Rodin Therapeutics in November 2019 for $100M upfront plus up to $850M in clinical, regulatory and sales milestones (~$950M total; closed Nov 25, 2019). The deal added Rodin's preclinical, orally available, brain-penetrant CoREST-selective HDAC inhibitors targeting synaptopathies in neurodegenerative disease. The lead asset, ALKS 1140 (formerly RDN-929), entered a first-in-human Phase 1 study (NCT05019105) with first subject dosed in late 2021, but Alkermes terminated that study on Aug 23, 2022 by "Sponsor Decision" after enrolling 20 of a planned cohort. No successor HDAC-CoREST program has since appeared in Alkermes' pipeline: the company separated its oncology business (Mural Oncology) in November 2023 to become a pure-play neuroscience company centered on the orexin OX2R agonist ALKS 2680. The ~$850M milestone tail is therefore effectively unrealizable and the acquired program is discontinued.

Did it work? Outcome assessment

Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
The deal was structured as a modest upfront with up to $950M in development/regulatory milestones; the lead HDAC-CoREST program (RDN-929 / ALKS-1140) was discontinued and Alkermes deprioritized novel CNS discovery, indicating the bulk of milestone value was never earned and acquired IPR&D was written down rather than realized.
Pipeline outcome
Assets Terminated
RDN-929/ALKS-1140, the brain-permeable HDAC-CoREST inhibitor for synaptopathies that was the centerpiece of the acquisition, carries a 'Discontinued' R&D status. Alkermes shifted strategy over the window, spinning out its oncology assets into Mural Oncology (2023) and concentrating on its marketed neuroscience franchise rather than the Rodin discovery platform.

Key facts

Disease & market context

Alzheimer's Disease and other neurodegenerative synaptopathies

$1.5B US Alzheimer's drug market 2024 · ~7.2M Projected US AD patients aged 65+ in 2025

Disease Overview

Alzheimer's disease and related synaptopathies are characterized by progressive synaptic loss and dysfunction in the brain, leading to memory impairment, cognitive decline, and ultimately loss of independence. Despite recent amyloid-targeted approvals, no therapy has restored or rebuilt synaptic connections — the structural deficit underlying symptoms — making epigenetic synaptogenesis approaches an attractive frontier.

Competitive Landscape

The Alzheimer's market shifted decisively after the 2019 deal date with the FDA approvals of Biogen/Eisai's Aduhelm (2021, since withdrawn) and Leqembi (lecanemab, 2023), and Eli Lilly's Kisunla (donanemab, 2024), all anti-amyloid antibodies that modestly slow decline. Symptomatic options remain dominated by generic cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, often combined as Namzaric. Rodin's selective HDAC-CoREST inhibitors offered a fundamentally different epigenetic synaptogenesis hypothesis — reactivating neuronal gene expression to strengthen and create new synapses, with a class profile designed to avoid the hematologic toxicity that plagued earlier pan-HDAC inhibitors (LifeSciVC: https://lifescivc.com/2019/11/thinking-boldly-alkermes-acquires-rodin-therapeutics/). Alkermes paid $100M upfront with $850M in milestones to expand from psychiatry into neurodegeneration. Outcome: Alkermes initiated a Phase 1 study of ALKS 1140 (the lead CoREST-selective HDAC inhibitor) in November 2021, but the asset has since been listed as discontinued and does not appear on Alkermes' 2024 pipeline disclosures, which now centers on orexin agonists (alixorexton/ALKS 2680) and commercial products Vivitrol, Aristada, and Lybalvi (FierceBiotech: https://www.fiercepharma.com/pharma/jpm24-after-transformational-year-alkermes-moves-pure-play-neuroscience-specialist).

Deal timeline

Related deals — scored

DealYearValueOutcome
Alkermes plc / Rodin Therapeutics, Inc. (this deal)2019$950M
Alkermes plc / Cephalon, Inc. (Vivitrol rights)2008$27M83
Alkermes plc / Avadel Pharmaceuticals plc2025$2.1B
Novartis AG / Advanced Accelerator Applications S.A.2017$3.9B98
Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program)2015$250M91
Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon)2000$450M89
Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals2015$3.5B86

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →